Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib

On November 16th, 2011, ruxolitinib was approved by the FDA for treatment of intermediate and high-risk myelofibrosis (MF). Before this, a variety of treatments were used for myelofibrosis, with variable efficacy.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Andrew Kuykendall, Najla Al Ali, Chetasi Talati, Eric Padron, David Sallman, Jeffrey Lancet, Alan List, Kenneth Zuckerman, Rami Komrokji Source Type: research